Darzalex Secures Breakthrough Therapy Designation
July 26, 2016
The mAb, in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, was granted a Breakthrough Therapy Designation from FDA for the treatment of multiple myeloma.